Ultragenyx Pharmaceutical is reducing its employee count. Approximately 130 employees will be laid off. This follows failed late-stage trials for a bone disorder. The FDA also requested more documentation for a gene therapy application. The company aims to cut expenses and focus resources on key drivers.
https://www.fiercebiotech.com/biotech/ultragenyx-lays-10-workforce-wake-phase-3-brittle-bone-trial-fails